Biomaterial-Facilitated Immunotherapy for Established Oral Cancers

We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nit...

Full description

Saved in:
Bibliographic Details
Published in:ACS biomaterials science & engineering 2021-02, Vol.7 (2), p.415-421
Main Authors: Leach, David G, Dharmaraj, Neeraja, Lopez-Silva, Tania L, Venzor, Jose Rodriguez, Pogostin, Brett H, Sikora, Andrew G, Hartgerink, Jeffrey D, Young, Simon
Format: Article
Language:English
Subjects:
Animals
Biocompatible Materials
Drug Liberation
Hydrogels
Immunotherapy
Mice
Mouth Neoplasms - therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nitric oxide synthase (iNOS) inhibition with controlled delivery of CDNs, demonstrating between 4- and 20-fold slower drug release than commercially available hydrogels. SynerGel allowed for immune-mediated elimination of established treatment-resistant oral tumors in a murine model, with a median survival of 67.5 days compared with 44 days in no-treatment control. This report details findings for a promising therapy showing improved efficacy over previous hydrogel systems.
ISSN:2373-9878
2373-9878
DOI:10.1021/acsbiomaterials.0c01575